Quarterly rpt on consolidated results for the financial period ended 30 Jun 2026

IHH HEALTHCARE BERHAD

Financial Year End	31 Dec 2026
Quarter	2 Qtr
Quarterly report for the financial period ended	30 Jun 2026
The figures	have not been audited

Attachments

IHH Q2 2026_Quarterly Report.pdf
420.0 kB

IHH Q2 2026_Press Release 27.08.2026.pdf
270.0 kB

Default Currency | Other Currency

Currency: **Malaysian Ringgit (MYR)**

SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2026

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2026	30 Jun 2025	30 Jun 2026	30 Jun 2025
		MYR'000	MYR'000	MYR'000	MYR'000
1	Revenue	7,046,000	6,298,000	13,599,000	12,592,000
2	Profit/(loss) before tax	1,032,000	727,000	2,004,000	1,489,000
3	Profit/(loss) for the period	723,000	567,000	1,398,000	1,192,000
4	Profit/(loss) attributable to ordinary equity holders of the parent	573,000	443,000	1,101,000	957,000
5	Basic earnings/(loss) per share (Subunit)	6.48	5.02	12.46	10.85
6	Proposed/Declared dividend per share (Subunit)	5.50	5.00	5.50	5.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END	
7	Net assets per share attributable to ordinary equity holders of the parent		3.5400		3.4300

Definition of Subunit:

In a currency system, there is usually a main unit (base) and subunit that is a fraction amount of the main unit. Example for the subunit as follows:

Country	Base Unit	Subunit
Malaysia	Ringgit	Sen
United States	Dollar	Cent
United Kingdom	Pound	Pence

Announcement Info

Company Name	IHH HEALTHCARE BERHAD
Stock Name	IHH
Date Announced	27 Aug 2026
Category	Financial Results
Reference Number	FRA-10082026-00010

IHH HEALTHCARE BERHAD
(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT
30 JUNE 2026

IHH HEALTHCARE BERHAD
Registration No. 201001018208 (901914-V)
(Incorporated in Malaysia)

UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

		2nd quarter ended			Financial period ended		
	Note	30 Jun 2026	30 Jun 2025	Variance	30 Jun 2026	30 Jun 2025	Variance
		RM'mil	RM'mil	%	RM'mil	RM'mil	%
Revenue	1	7,046	6,298	12%	13,599	12,592	8%
Other operating income		111	96	16%	233	197	18%
Inventories and consumables		(1,436)	(1,292)	-11%	(2,712)	(2,566)	-6%
Purchased and contracted services		(514)	(522)	2%	(1,022)	(1,004)	-2%
Staff costs	2	(2,806)	(2,451)	-14%	(5,454)	(4,966)	-10%
Depreciation and impairment of property, plant and equipment		(374)	(342)	-9%	(729)	(689)	-6%
Depreciation of right-of-use ("ROU") assets		(116)	(108)	-7%	(227)	(219)	-4%
Amortisation of intangible assets	3	(51)	(12)	NM	(75)	(24)	NM
Operating lease expenses		(38)	(32)	-19%	(76)	(63)	-21%
Other operating expenses		(751)	(743)	-1%	(1,514)	(1,489)	-2%
Finance income		97	69	41%	155	126	23%
Finance costs		(280)	(257)	-9%	(555)	(539)	-3%
Net monetary gain arising from hyperinflationary economy		136	15	NM	365	118	NM
Share of profits of associates (net of tax)		8	8	0%	15	14	7%
Share of profits of joint ventures (net of tax)		-	-	-	1	1	0%
Profit before tax		**1,032**	**727**	**42%**	**2,004**	**1,489**	**35%**
Income tax expense	4	(309)	(160)	-93%	(606)	(297)	-104%
Profit for the period		**723**	**567**	**28%**	**1,398**	**1,192**	**17%**
Other comprehensive income, net of tax							
Items that are or may be reclassified subsequently to profit or loss							
Foreign currency translation differences from foreign operations	5	470	(109)	NM	(326)	(56)	NM
Realisation of FCTR[1] upon liquidation of a joint venture		93	-	-	(48)	-	-
Hyperinflationary adjustments		538	(199)	NM	758	(170)	NM
Hedge of net investments in foreign operations		10	37	-73%	55	(32)	NM
Cash flow hedge		(46)	(102)	55%	(73)	(164)	55%
Costs of hedging		(2)	1	NM	(3)	5	-160%
		1,063	(372)	NM	363	(417)	187%
Items that will not be reclassified subsequently to profit or loss							
Remeasurement of defined benefit liabilities		(13)	(7)	-86%	(28)	(19)	-47%
Total other comprehensive income for the period, net of tax		**1,050**	**(379)**	**NM**	**335**	**(436)**	**177%**
Total comprehensive income for the period		**1,773**	**188**	**NM**	**1,733**	**756**	**129%**
Profit attributable to:							
Owners of the Company		573	443	29%	1,101	957	15%
Non-controlling interests		150	124	21%	297	235	26%
Profit for the period		**723**	**567**	**28%**	**1,398**	**1,192**	**17%**
Total comprehensive income attributable to:							
Owners of the Company		1,504	144	NM	1,529	639	139%
Non-controlling interests		269	44	NM	204	117	74%
Total comprehensive income for the period		**1,773**	**188**	**NM**	**1,733**	**756**	**129%**
Earnings per share (sen)							
Basic		6.48	5.02	29%	12.46	10.85	15%
Diluted		6.48	5.02	29%	12.46	10.85	15%

NM: Not meaningful
Note:
[1]: Foreign currency translation reserve

.

UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

SUPPLEMENTARY INFORMATION

	Note	2nd quarter ended 30 Jun 2026 RM'mil	2nd quarter ended 30 Jun 2025 RM'mil	Variance %	Financial period ended 30 Jun 2026 RM'mil	Financial period ended 30 Jun 2025 RM'mil	Variance %
Profit attributable to owners of the Company, excluding EI[iv]		**569**	**419**	**36%**	**1,028**	**844**	**22%**
Add/(Less): Exceptional items ("EI")							
Reversal of impairment for investment in associate		1	-		-	-	
Exchange difference on net borrowings[i]		(6)	15		(13)	10	
Deferred tax debits[ii]		(127)	-		(274)	-	
Net monetary gain arising from hyperinflationary economy[iii]		136	15		365	118	
		4	30		78	128	
Less: Tax effects on EI		1	(3)		3	(2)	
Less: Non-controlling interests' share of EI		(1)	(3)		(8)	(13)	
		4	24		73	113	
Profit attributable to owners of the Company		**573**	**443**	**29%**	**1,101**	**957**	**15%**
Earnings per share, excluding EI[iv] (sen)							
Basic		6.44	4.75	36%	11.63	9.57	22%
Diluted		6.44	4.75	36%	11.63	9.57	22%

Note:
"Acibadem Holdings" as referred to throughout this financial report includes the wholly-owned Integrated Healthcare Turkey Yatirimlari Limited Group, which owns approximately 90% interest in Acıbadem Saglik Yatirimlari Holding A.S. Group.

i) Exchange differences arising from foreign currency denominated borrowings, lease liabilities, payables, cash and receivables, recognised by Acibadem Holdings.
ii) Deferred tax debits arising from the change in regulations in Turkiye to disallow revaluation of certain assets (based on inflation index) in the tax financials of entities in Turkiye, from 2025 till 2027, with possibility of extension for another 3 years (ie. reversing the regulation in 2023 that allows revaluing of assets in tax financials to reflect prevailing inflation).
iii) Net increase in purchasing power from the net monetary position of the Group's operations in Turkiye, upon the application of MFRS 129, *Financial Reporting in Hyperinflationary Economies*.
iv) Net of non-controlling interests and tax

EXPLANATORY NOTES TO THE STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

The Group's reported results, across the periods, was impacted by the relative movements of Ringgit Malaysia ("RM") against the exchange rates of the countries that the Group operates in. The RM strengthened against Singapore Dollars ("SGD") and Turkish Lira ("TL") in the current period as compared to the corresponding period last year.

The Group's reported results, across the periods, was also impacted by the relative movements of inflation rates in Turkiye, upon the application of MFRS 129, *Financial Reporting in Hyperinflationary Economies* ("MFRS 129") to the Group's entities in Turkiye. Refer to Section A4 for details.

In addition to variances arising from the above-mentioned effects of the relative movement in exchange rates and inflation rates in Turkiye, the following notes explain the major fluctuations in the statement of profit or loss and other comprehensive income for the period ended 30 June 2026.

Refer to Section B1 for performance review of the Group's major operating segments.

1. Revenue increased as a result of sustained demand for quality healthcare services, a case-mix of more acute patients and price adjustments to counter inflation. The consolidation of Bayindir Healthcare, TMI Healthcare and Biruni Labs, which were acquired in July 2025, January 2026 and June 2026 respectively, also contributed to the increase in revenue.
2. Q2 2026 staff costs increased as the Group expands its capacity to cater for higher demand for its services and annual increment. Staff costs also increased as a result of changes in regulations, such as the new labour code in India which was effective from November 2025.
3. During the period, the Group reclassified software costs capitalised under property, plant and equipment to intangible assets, resulting in an increase in amortisation of intangible assets which is offset by a corresponding decrease in depreciation expense.

   In addition, amortisation expense increased with the increase of intangible assets arising from the acquisition of subsidiaries.
4. Refer to Section B5 for details on income tax expenses.
5. The Group's foreign currency translation differences from foreign operations arise mainly from the translation of the net assets of its Singapore, India, Turkiye and Europe operations.

   Parkway Life Real Estate Investment Trust ("PLife REIT") hedges its interest in the net assets of its Japanese operations. The effective portion of the hedge was recognised as a hedge of net investments in the statement of other comprehensive income, which offsets the foreign currency translation differences from the translation of the net assets of its Japanese operations.

Note:
Key exchange rates used to translate the YTD results of overseas subsidiaries into RM:

	30 Jun 2026	30 Jun 2025
1 SGD	3.1155	3.3053
1 TL	0.0885	0.1070

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2026

	Note	30 Jun 2026 RM'mil	31 Dec 2025 RM'mil
Assets			
Property, plant and equipment	1	17,990	17,665
Right-of-use assets		7,866	7,781
Investment properties		4,427	4,521
Goodwill on consolidation	2	15,933	15,639
Other intangible assets	1	4,295	3,851
Interests in associates		165	167
Interests in joint ventures		15	15
Other financial assets		230	222
Trade and other receivables		227	280
Tax recoverables		408	437
Derivative assets		80	80
Deferred tax assets		337	302
Total non-current assets		**51,973**	**50,960**
Development properties			
- medical suites		88	80
Inventories	3	965	719
Trade and other receivables	4	3,745	3,365
Tax recoverables		128	191
Other financial assets		492	692
Derivative assets		17	15
Cash and cash equivalents		1,412	1,595
Total current assets		**6,847**	**6,657**
Total assets		**58,820**	**57,617**

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2026

	Note	30 Jun 2026 RM'mil	31 Dec 2025 RM'mil
Equity			
Share capital		19,894	19,894
Other reserves		(150)	(405)
Retained earnings		11,561	10,814
Total equity attributable to owners of the Company		**31,305**	**30,303**
Non-controlling interests		3,883	3,798
Total equity		**35,188**	**34,101**
Liabilities			
Loans and borrowings	5	7,107	7,734
Lease liabilities		1,973	1,955
Employee benefits		281	252
Trade and other payables		327	305
Derivative liabilities		25	36
Deferred tax liabilities		2,192	1,840
Total non-current liabilities		**11,905**	**12,122**
Bank overdrafts		80	52
Loans and borrowings	5	5,789	5,598
Lease liabilities		232	200
Employee benefits		204	205
Trade and other payables		5,010	4,939
Derivative liabilities		24	37
Tax payable		388	363
Total current liabilities		**11,727**	**11,394**
Total liabilities		**23,632**	**23,516**
Total equity and liabilities		**58,820**	**57,617**
Net assets per share attributable to owners of the Company[1] (RM)		3.54	3.43

[1]: Based on 8,836 million and 8,836 million shares issued as at 30 June 2026 and 31 December 2025 respectively.

The unaudited Consolidated Statement of Financial Position should be read in conjunction with the 2025 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

EXPLANATORY NOTES TO THE STATEMENT OF FINANCIAL POSITION

The Group's reported financial position as at 30 June 2026 was impacted by the movements in RM against the exchange rates of the countries that the Group operates in. The RM strengthened against SGD and TL for the period ended 30 June 2026.

The Group's reported financial position as at 30 June 2026 was also impacted by the movements of the price index in Turkiye, upon the application of MFRS 129 to the Group's entities in Turkiye. Inflation rates in Turkiye increased for the period ended 30 June 2026. Refer to Section A4 for details.

In addition to variances arising from the above-mentioned effects of the movement in exchange rates and inflation rates in Turkiye, the following notes explain the major fluctuations in the statement of financial position as at 30 June 2026.

1. The Group reclassified approximately RM200 million of software costs capitalised under property, plant and equipment to intangible assets.
2. The Group recorded RM160 million of goodwill from the acquisition of TMI Healthcare and Biruni Labs. Refer to Section A11 for details.
3. Inventories increased mainly due to higher revenue and inventory stock-up in anticipation of potential supply chain uncertainties.
4. Trade and other receivables increased mainly due to higher revenue.
5. Loans and borrowings decreased due to net repayment during the period.

Note:
Key closing exchange rates used to translate the financial position of overseas subsidiaries into RM:

	30 Jun 2026	31 Dec 2025
1 SGD	3.1847	3.1878
1 TL	0.0885	0.0950

IHH HEALTHCARE BERHAD
Registration No. 201001018208 (901914-V)
(Incorporated in Malaysia)

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2026

	<---------- Attributable to owners of the Company ---------->												
	<---------- Non-distributable ---------->									Distributable			
	Share capital RM'mil	Share option reserve RM'mil	Revaluation reserve RM'mil	Fair value reserve RM'mil	Hedge reserve RM'mil	Cost of hedging reserve RM'mil	Capital reserve RM'mil	Legal reserve RM'mil	Foreign currency translation reserve RM'mil	Retained earnings RM'mil	Total RM'mil	Non-controlling interests RM'mil	Total equity RM'mil
At 1 January 2026	19,894	-	159	47	(277)	3	(3,909)	52	3,520	10,814	30,303	3,798	34,101
Foreign currency translation differences from foreign operations	-	-	-	-	-	-	-	-	(152)	-	(152)	(174)	(326)
Realisation of FCTR upon liquidation of a joint venture	-	-	-	-	-	-	-	-	(48)	-	(48)	-	(48)
Hyperinflationary adjustments	-	-	-	-	36	-	53	-	460	159	708	50	758
Hedge of net investments in foreign operations	-	-	-	-	-	-	-	-	18	-	18	37	55
Cash flow hedge	-	-	-	-	(72)	-	-	-	-	-	(72)	(1)	(73)
Costs of hedging	-	-	-	-	-	(1)	-	-	-	-	(1)	(2)	(3)
Remeasurement of defined benefit liabilities	-	-	-	-	-	-	-	-	-	(25)	(25)	(3)	(28)
Total other comprehensive income for the period	-	-	-	-	(36)	(1)	53	-	278	134	428	(93)	335
Profit for the period	-	-	-	-	-	-	-	-	-	1,101	1,101	297	1,398
Total comprehensive income for the period	-	-	-	-	(36)	(1)	53	-	278	1,235	1,529	204	1,733
Contributions by and distributions to owners													
Share-based payment transactions	-	3	-	-	-	-	-	-	-	-	3	8	11
Dividends to owners of the Company	-	-	-	-	-	-	-	-	-	(486)	(486)	-	(486)
Dividends to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	(122)	(122)
Remeasurement of liabilities on put options granted to non-controlling interests	-	-	-	-	-	-	(39)	-	(5)	-	(44)	(5)	(49)
Transfer per statutory requirements	-	-	-	-	-	-	-	2	-	(2)	-	-	-
Total transactions with owners	-	3	-	-	-	-	(39)	2	(5)	(488)	(527)	(119)	(646)
At 30 June 2026	19,894	3	159	47	(313)	2	(3,895)	54	3,793	11,561	31,305	3,883	35,188

IHH HEALTHCARE BERHAD
Registration No. 201001018208 (901914-V)
(Incorporated in Malaysia)

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2026

	Attributable to owners of the Company												
	Non-distributable									Distributable			
	Share capital RM'mil	Share option reserve RM'mil	Revaluation reserve RM'mil	Fair value reserve RM'mil	Hedge reserve RM'mil	Cost of hedging reserve RM'mil	Capital reserve RM'mil	Legal reserve RM'mil	Foreign currency translation reserve RM'mil	Retained earnings RM'mil	Total RM'mil	Non-controlling interests RM'mil	Total equity RM'mil
At 1 January 2025	19,739	21	159	47	(120)	(1)	(4,010)	52	4,545	9,708	30,140	3,768	33,908
Foreign currency translation differences from foreign operations	-	-	-	-	-	-	-	-	16	-	16	(72)	(56)
Hyperinflationary adjustments	-	-	-	-	42	-	28	(2)	(205)	(31)	(168)	(2)	(170)
Hedge of net investments in foreign operations	-	-	-	-	-	-	-	-	(11)	-	(11)	(21)	(32)
Cash flow hedge	-	-	-	-	(142)	-	-	-	-	-	(142)	(22)	(164)
Costs of hedging	-	-	-	-	-	2	-	-	-	-	2	3	5
Remeasurement of defined benefit liabilities	-	-	-	-	-	-	-	-	-	(15)	(15)	(4)	(19)
Total other comprehensive income for the period	-	-	-	-	(100)	2	28	(2)	(200)	(46)	(318)	(118)	(436)
Profit for the period	-	-	-	-	-	-	-	-	-	957	957	235	1,192
Total comprehensive income for the period	-	-	-	-	(100)	2	28	(2)	(200)	911	639	117	756
Contributions by and distributions to owners													
Share-based payment transactions	-	1	-	-	-	-	-	-	-	-	1	-	1
Transfer to share capital for share options exercised	155	(19)	-	-	-	-	-	-	-	-	136	-	136
Cancellation of vested share options	-	(3)	-	-	-	-	-	-	-	3	-	-	-
Dividends to owners of the Company	-	-	-	-	-	-	-	-	-	(485)	(485)	-	(485)
Dividends to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	(40)	(40)
Issue of shares by a subsidiary to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	14	14
Remeasurement of liabilities on put options granted to non-controlling interests	-	-	-	-	-	-	(10)	-	(42)	-	(52)	(6)	(58)
Transfer per statutory requirements	-	-	-	-	-	-	-	1	-	(1)	-	-	-
	155	(21)	-	-	-	-	(10)	1	(42)	(483)	(400)	(32)	(432)
Changes in ownership interests in subsidiaries	-	-	-	-	-	-	83	-	-	-	83	(67)	16
Total transactions with owners	155	(21)	-	-	-	-	73	1	(42)	(483)	(317)	(99)	(416)
At 30 June 2025	19,894	-	159	47	(220)	1	(3,909)	51	4,303	10,136	30,462	3,786	34,248

The unaudited Consolidated Statement of Changes in Equity should be read in conjunction with the 2025 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2026

	Financial period ended	
	30 Jun 2026	30 Jun 2025
	RM'mil	RM'mil
Cash flows from operating activities		
Profit before tax	2,004	1,489
Adjustments for:		
Dividend income	(2)	(1)
Finance income	(155)	(126)
Finance costs	555	539
Depreciation and impairment of property, plant and equipment	729	689
Depreciation of ROU assets	227	219
Amortisation of intangible assets	75	24
Impairment loss made:		
- Trade and other receivables	38	39
Write-off:		
- Property, plant and equipment	5	1
- Trade and other receivables	9	5
- Inventories	3	3
Gain on disposal of property, plant and equipment	(6)	(3)
Gain on disposal of an investment property	(2)	-
Share of profits of associates (net of tax)	(15)	(14)
Share of profits of joint ventures (net of tax)	(1)	(1)
Equity-settled share-based payment	11	1
Net monetary gain arising from hyperinflationary economy	(365)	(118)
Operating profit before changes in working capital	**3,110**	**2,746**
Changes in working capital:		
Development properties	(8)	-
Inventories	(230)	(54)
Trade and other receivables	(516)	(312)
Trade and other payables	314	420
Cash generated from operations	**2,670**	**2,800**
Tax paid	(267)	(319)
Net cash from operating activities	**2,403**	**2,481**
Cash flows from investing activities		
Interest received	153	93
Acquisition of subsidiaries, net of cash and cash equivalents acquired	(166)	-
Purchase of other financial assets	(1,205)	(945)
Net withdrawal/(placement) of fixed deposits with tenor of more than 3 months	67	(42)
Purchase of property, plant and equipment	(1,521)	(2,012)
Cost capitalised and purchase of investment properties	(12)	(20)
Development and purchase of intangible assets	(99)	(123)
Proceeds from disposal of other financial assets	1,338	1,281
Proceeds from disposal of property, plant and equipment	13	2
Proceeds from disposal of an investment property	30	-
Dividends received from associates and joint ventures	12	2
Net cash used in investing activities	**(1,390)**	**(1,764)**

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2026

	Financial period ended	
	30 Jun 2026	30 Jun 2025
	RM mil	RM mil
Cash flows from financing activities		
Finance costs paid	(359)	(310)
Proceeds from loans and borrowings	3,754	2,683
Repayment of loans and borrowings	(4,031)	(1,747)
Payment of lease liabilities	(271)	(196)
Dividends paid to owners of the Company	(486)	(485)
Dividends paid to non-controlling interests	(122)	(40)
Proceeds from exercise of share options	-	136
Acquisition of non-controlling interests	-	(686)
Proceeds from issue of shares by a subsidiary to non-controlling interests	-	14
Net cash used in financing activities	**(1,515)**	**(631)**
Net (decrease)/increase in cash and cash equivalents	**(502)**	**86**
Effect of exchange rate fluctuations on cash and cash equivalents held	291	(25)
Cash and cash equivalents at beginning of the period	1,543	1,427
Cash and cash equivalents at end of the period	**1,332**	**1,488**

Cash and cash equivalents

Cash and cash equivalents in the statement of cash flows comprises the following amounts from the statement of financial position:

	Financial period ended	
	30 Jun 2026	30 Jun 2025
	RM mil	RM mil
Cash and bank balances	1,209	1,382
Fixed deposits with tenor of 3 months or less	203	135
Deposits placed in escrow account	-	17
Cash and cash equivalents in the statement of financial position	1,412	1,534
Less:		
- Bank overdrafts	(80)	(46)
Cash and cash equivalents in the statement of cash flows	**1,332**	**1,488**

Deposits placed in escrow account

These were the amounts deposited in accordance with the requirements of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers Regulations) (“SEBI (SAST) Regulations”) relating to the Group’s Mandatory Open Offer (“Offer”) to acquire up to an additional 197,025,660 and 4,894,308 equity shares of Fortis Healthcare Limited (“Fortis”) and Fortis Malar Hospitals Limited (“Malar”) respectively. These amounts could only be released in the manner prescribed in Clause 17(10) of the SEBI (SAST) Regulations.

On 10 November 2025, the Offer was completed.

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

A1 BASIS OF PREPARATION

a) Basis of accounting

These unaudited consolidated interim financial report are prepared in accordance with the applicable disclosure provisions of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, MFRS 134, *Interim Financial Reporting* in Malaysia and IAS 34, *Interim Financial Reporting*. They do not include all of the information required for full annual financial statements and certain financial information in this unaudited consolidated interim financial report were extracted from the audited financial statements. Therefore, it should be read in conjunction with the audited consolidated financial statements of the Group for the financial year ended 31 December 2025 ("2025 Audited Financial Statements").

The 2025 Audited Financial Statements were prepared in accordance with MFRS Accounting Standards as issued by the Malaysian Accounting Standards Board ("MFRS Accounting Standards").

b) Material accounting policies

The accounting policies and presentation adopted for this consolidated interim financial report are consistent with those adopted for the 2025 Audited Financial Statements, except for the adoption of the following amendment to MFRS Accounting Standards as issued by the Malaysian Accounting Standards Board ("MASB").

Amendments effective for annual periods beginning on or after 1 January 2026

- Amendments to MFRS 9, *Financial Instruments* and MFRS 7, *Financial Instruments: Disclosures – Classification and Measurement of Financial Instruments*
- Amendments that are part of Annual Improvements ─ Volume 11:
  - Amendments to MFRS 1, *First-time Adoption of Malaysian Financial Reporting Standards*
  - Amendments to MFRS 7, *Financial Instruments: Disclosures*
  - Amendments to MFRS 9, *Financial Instruments*
  - Amendments to MFRS 10, *Consolidated Financial Statements*
  - Amendments to MFRS 107, *Statement of Cash Flows*
- Amendments to MFRS 9, *Financial Instruments* and MFRS 7, *Financial Instruments: Disclosures – Contracts Referencing Nature-dependent Electricity*

A2 AUDIT REPORT IN THE ANNUAL FINANCIAL STATEMENTS

The 2025 Audited Financial Statements were not subjected to any qualification.

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

A3 SEASONALITY OF OPERATIONS

Inpatient and outpatient revenue and volume are generally lower during festive periods and summer months in each of the relevant countries in which the Group operates and other holiday periods. Conversely, patient volumes and thus inpatient and outpatient revenue are highest during the winter months in some markets. As the Group is continuously expanding, the effects of seasonality may not be obvious from the Group's financial statements.

A4 SIGNIFICANT UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS

There were no unusual items affecting assets, liabilities, equity, net income or cash flows due to their nature, size or incidence for the financial period ended 30 June 2026, other than the effects of the application of MFRS 129 to the Group's entities in Turkiye below.

Effects of application of MFRS129

Statement of profit or loss	Before hyperinflationary adjustments RM'mil	Adjustments RM'mil	After hyperinflationary adjustments RM'mil
Revenue	13,387	212	13,599
Other operating income	229	4	233
Inventories and consumables	(2,658)	(54)	(2,712)
Purchased and contracted services	(1,019)	(3)	(1,022)
Staff costs	(5,337)	(117)	(5,454)
Depreciation and impairment of property, plant and equipment	(567)	(162)	(729)
Depreciation of ROU assets	(181)	(46)	(227)
Amortisation of intangible assets	(53)	(22)	(75)
Operating lease expenses	(74)	(2)	(76)
Other operating expenses	(1,497)	(17)	(1,514)
Finance income	149	6	155
Finance costs	(535)	(20)	(555)
Net monetary gain arising from hyperinflationary economy	-	365	365
Share of profits of associates (net of tax)	15	-	15
Share of profits of joint ventures (net of tax)	1	-	1
Profit before tax	**1,860**	**144**	**2,004**
Income tax expense	(332)	(274)	(606)
Profit for the period	**1,528**	**(130)**	**1,398**
Profit attributable to:			
Owners of the Company	1,215	(114)	1,101
Non-controlling interests	313	(16)	297
Profit for the period	**1,528**	**(130)**	**1,398**

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

Statement of financial position	Before hyperinflationary adjustments RM'mil	Adjustments RM'mil	After hyperinflationary adjustments RM'mil
Non-current assets			
Property, plant and equipment	15,225	2,765	17,990
Right-of-use assets	6,944	922	7,866
Goodwill on consolidation	13,997	1,936	15,933
Other intangible assets	2,989	1,306	4,295
Trade and other receivables	223	4	227
Deferred tax assets	336	1	337
Curent assets			
Inventories	932	33	965
Equity			
Other reserves	(5,280)	5,130	(150)
Retained earnings	11,122	439	11,561
Non-controlling interests	3,267	616	3,883
Non-current liabiliities			
Deferred tax liabilities	1,410	782	2,192

A5 CHANGE IN ACCOUNTING ESTIMATES

There were no changes in the estimates of amounts reported in prior financial years that may have a material effect in the current quarter and financial period.

In preparing the unaudited consolidated interim financial report, the significant judgments made by the management in applying the Group's accounting policies and key sources of estimating uncertainty were consistent with those applied to the 2025 Audited Financial Statements.

A6 DEBT AND EQUITY SECURITIES

There were no issuance of shares, share buy-backs and repayments of debt and equity securities by the Company during the financial period from 1 January 2026 to 30 June 2026.

As at 30 June 2026, the issued share capital of the Company comprised of 8,836,153,463 ordinary shares.

A7 DIVIDENDS PAID

	Per ordinary share Sen	Total amount RM'mil	Date of payment
As at 30 June 2026			
Final single tier cash dividend for the financial year ended 31 December 2025	5.50	486	30-Apr-26
As at 30 June 2025			
Final single tier cash dividend for the financial year ended 31 December 2024	5.50	485	28-Apr-25

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

A8 SEGMENT REPORTING

There has been no significant changes in the basis of segmentation or in the basis of measurement of segment profit or loss from the 2025 Audited Financial Statements.

The Group's reportable segments comprise:

- Hospital and healthcare
  - Singapore
  - Malaysia
  - India
  - Greater China
  - Turkiye and Europe
  - Southeast Asia
- Labs
- PLife REIT
- Others

Except for Labs and PLife REIT, the strategic business units offer hospital and healthcare services in different locations and are managed separately. Labs is a diagnostic laboratory service provider, while PLife REIT is a real estate investment trust. Others comprises the Group's corporate office as well as other investment holding entities.

Management monitors the operating results of each business unit for the purpose of making decisions on resource allocation and performance assessment. Performance is measured based on segment earnings before interest, tax, depreciation, amortisation, exchange differences and other non-operational items ("EBITDA").

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

A8 SEGMENT REPORTING

Financial period ended 30 June 2026

	Hospital and Healthcare												
	Singapore RM'mil	Malaysia RM'mil	India RM'mil	Greater China RM'mil	Turkiye and Europe RM'mil	Southeast Asia RM'mil	Labs RM'mil	PLife REIT RM'mil	Others RM'mil	Eliminations RM'mil	Total (Without MFRS129) RM'mil	MFRS129 RM'mil	Total RM'mil
Revenue and expenses													
Revenue from external customers	2,705	2,537	2,026	832	4,721	-	484	77	5	-	13,387	212	13,599
Inter-segment revenue	5	4	7	-	-	-	330	157	332	(835)	-	-	-
Total segment revenue	2,710	2,541	2,033	832	4,721	-	814	234	337	(835)	13,387	212	13,599
EBITDA	750	689	385	89	974	-	177	189	177	(411)	3,019	23	3,042
Depreciation and impairment of property, plant and equipment	(108)	(142)	(74)	(49)	(159)	-	(17)	(14)	(4)	-	(567)	(162)	(729)
Depreciation of ROU assets	(153)	(20)	(16)	(22)	(55)	-	(18)	(7)	(4)	114	(181)	(46)	(227)
Amortisation of intangible assets	(13)	(6)	(8)	(4)	(10)	-	(8)	-	(9)	5	(53)	(22)	(75)
Foreign exchange differences	-	(1)	1	-	4	-	1	11	(4)	-	12	-	12
Finance income	4	3	-	-	127	-	13	1	35	(34)	149	6	155
Finance costs	(78)	(68)	(70)	(70)	(318)	-	(6)	(26)	(11)	112	(535)	(20)	(555)
Net monetary gain arising from hyperinflationary economy	-	-	-	-	-	-	-	-	-	-	-	365	365
Share of profits of associates (net of tax)	1	-	4	-	-	10	-	-	-	-	15	-	15
Share of profits of joint ventures (net of tax)	1	-	-	-	-	-	-	-	-	-	1	-	1
Profit/(Loss) before tax	404	455	222	(56)	563	10	142	154	180	(214)	1,860	144	2,004
Income tax expense	(76)	(131)	(48)	-	(28)	-	(33)	(9)	(7)	-	(332)	(274)	(606)
Profit/(Loss) for the period	328	324	174	(56)	535	10	109	145	173	(214)	1,528	(130)	1,398
Assets and liabilities													
Cash and cash equivalents	(2)	85	42	102	704	-	84	186	211	-	1,412	-	1,412
Other assets	19,661	11,779	5,996	2,788	7,822	69	2,075	5,990	5,149	(10,888)	50,441	6,967	57,408
Segment assets as at 30 June 2026	19,659	11,864	6,038	2,890	8,526	69	2,159	6,176	5,360	(10,888)	51,853	6,967	58,820
Loans and borrowings	-	3,602	1,057	3,359	1,343	-	3	2,847	685	-	12,896	-	12,896
Other liabilities	9,143	1,679	1,497	1,101	4,845	-	429	455	2,144	(11,339)	9,954	782	10,736
Segment liabilities as at 30 June 2026	9,143	5,281	2,554	4,460	6,188	-	432	3,302	2,829	(11,339)	22,850	782	23,632

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

Financial period ended 30 June 2025*

	Hospital and Healthcare												
	Singapore RM'mil	Malaysia RM'mil	India RM'mil	Greater China RM'mil	Turkiye and Europe RM'mil	Southeast Asia RM'mil	Labs RM'mil	PLife REIT RM'mil	Others RM'mil	Eliminations RM'mil	Total (Without MFRS129) RM'mil	MFRS129 RM'mil	Total RM'mil
Revenue and expenses													
Revenue from external customers	3,034	2,284	2,044	810	3,993	-	504	90	4	-	12,763	(171)	12,592
Inter-segment revenue	7	3	1	-	-	-	362	132	271	(776)	-	-	-
Total segment revenue	3,041	2,287	2,045	810	3,993	-	866	222	275	(776)	12,763	(171)	12,592
EBITDA	859	562	380	79	721	-	180	173	123	(318)	2,759	(62)	2,697
Depreciation and impairment of property, plant and equipment	(112)	(146)	(98)	(50)	(124)	-	(19)	(16)	(2)	-	(567)	(122)	(689)
Depreciation of ROU assets	(160)	(19)	(11)	(28)	(47)	-	(20)	(8)	(5)	119	(179)	(40)	(219)
Amortisation of intangible assets	-	(1)	(5)	(1)	(3)	-	(8)	-	(5)	5	(18)	(6)	(24)
Foreign exchange differences	-	-	(8)	1	8	-	(1)	14	(10)	-	4	-	4
Finance income	18	4	11	-	79	-	14	1	56	(52)	131	(5)	126
Finance costs	(84)	(85)	(75)	(91)	(271)	-	(8)	(41)	(29)	136	(548)	9	(539)
Net monetary gain arising from hyperinflationary economy	-	-	-	-	-	-	-	-	-	-	-	118	118
Share of profits of associates (net of tax)	1	-	4	-	-	9	-	-	-	-	14	-	14
Share of profits of joint ventures (net of tax)	1	-	-	-	-	-	-	-	-	-	1	-	1
Profit/(Loss) before tax	523	315	198	(90)	363	9	138	123	128	(110)	1,597	(108)	1,489
Income tax (expense)/credit	(93)	(100)	(52)	-	(16)	-	(31)	(11)	(3)	-	(306)	9	(297)
Profit/(Loss) for the period	430	215	146	(90)	347	9	107	112	125	(110)	1,291	(99)	1,192
Assets and liabilities													
Cash and cash equivalents	14	98	88	142	665	-	50	152	386	-	1,595	-	1,595
Other assets	20,133	11,551	6,096	2,695	7,494	72	2,099	6,041	5,938	(12,033)	50,086	5,936	56,022
Segment assets as at 31 December 2025	20,147	11,649	6,184	2,837	8,159	72	2,149	6,193	6,324	(12,033)	51,681	5,936	57,617
Loans and borrowings	-	4,235	1,365	3,343	1,427	-	1	2,815	146	-	13,332	-	13,332
Other liabilities	9,955	1,591	1,321	996	4,676	-	458	502	2,676	(12,440)	9,735	449	10,184
Segment liabilities as at 31 December 2025	9,955	5,826	2,686	4,339	6,103	-	459	3,317	2,822	(12,440)	23,067	449	23,516

*: Segment information on Assets and Liabilities is based on the last financial year-end.

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

A9 VALUATION OF PROPERTY, PLANT AND EQUIPMENT

The Group does not adopt a revaluation policy on its property, plant and equipment.

A10 SIGNIFICANT RELATED PARTY TRANSACTIONS

Related party transactions have been entered into in the normal course of business under negotiated terms. Other than the remuneration paid to the key management personnel, the significant related party transactions of the Group are as follows:

	Financial period ended	
	30 Jun 2026	30 Jun 2025
	RM'mil	RM'mil
Transactions with substantial shareholders*		
- Purchase and consumption of services	(14)	(12)
Transactions with key management personnel*		
- Sales and provision of services	5	6
- Purchase and consumption of services	(88)	(88)

*: Including parties directly/jointly-controlled by substantial shareholders or key management personnel.

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

A11 CHANGES IN THE COMPOSITION OF THE GROUP

(a) On 9 January 2026, International Hospital Limited ("IHL") completed the acquisition of 100% equity stake in TMI Healthcare Private Limited ("THPL") for a total consideration of INR4 billion (equivalent to RM170 million). THPL is primarily engaged in hospital and medical care services. Consequential thereto, THPL has become an indirect 31.17% owned subsidiary of IHH.

(b) On 19 February 2026, Parkway Life Real Estate Investment Trust ("PLife REIT") issued 166,139 new PLife REIT units being part payment of base fee component of the management fee due to Parkway Trust Management Limited ("PTM") for the period from 1 October 2025 to 31 December 2025, and management performance fee due to PTM for the period from 1 January 2025 to 31 December 2025. Consequential thereto, PTM's unitholdings in PLife REIT increased to 1,628,913 units, and IHH's effective indirect shareholding in PLife REIT increased from 32.94% to 32.96%.

(c) On 1 March 2026, Fortis Emergency Services Limited ("FESL"), Fortis Cancer Care Limited ("FCCL"), Fortis Health Management (East) Limited ("FHMEL") and Birdie & Birdie Realtors Private Limited ("BBRPL") merged with Fortis Hospitals Limited ("FHsL"). All assets and liabilities of FESL, FCCL, FHMEL and BBRPL were transferred to FHsL and these entities were deemed dissolved (without liquidation) following a composite scheme of merger. The internal reorganisation was undertaken in order to streamline the group structure.

(d) On 25 March 2026, Acıbadem City Clinic EAD ("ACC EAD"), an indirect 71.13% owned subsidiary of IHH, acquired the remaining 15% equity stake in Tokuda Clinical Research Center AD ("TCRC"). Consequential thereto, TCRC became a direct wholly-owned subsidiary of ACC EAD and IHH's effective indirect shareholding in TCRC increased from 60.46% to 71.13%.

(e) On 27 March 2026, Gleneagles Development Pte Ltd ("GDPL"), an indirect subsidiary of IHH, acquired 5,373,870 equity shares by way of rights issue by Gleneagles Healthcare India Private Limited ("GHIPL"), for a consideration of INR1,983 million (equivalent to RM84 million). Consequential thereto, IHH's effective indirect shareholding in GHIPL increased from 99.15% to 99.17%.

(f) On 13 April 2026, PTM transferred 180,000 PLife REIT units that it owned to its eligible employees in accordance with PTM's long term incentive plan. Consequential thereto, IHH Group's effective indirect shareholding in PLife REIT decreased from 32.96% to 32.93%.

(g) On 15 May 2026, PLife REIT issued 33,516 new PLife REIT units being part payment of base fee component of the management fee due to PTM for the period from 1 January 2026 to 31 March 2026. Consequential thereto, PTM's unitholdings in PLife REIT increased to 1,482,429 units, and IHH's effective indirect shareholding in PLife REIT increased from 32.93% to 32.94%.

(h) On 17 May 2026, Parkway Healthcare Indo-China Pte Ltd, an indirect wholly-owned subsidiary of IHH, has been struck off from the Register of Companies pursuant to Section 344A of the Singapore Companies Act 1967.

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

(i) On 2 June 2026, Acibadem Saglik Hizmetleri ve Ticaret A.S., an indirect subsidiary of IHH, completed the acquisition of entire equity interest in Biruni Laboratuvari Tibbi Tahliller Sanayi A.S. ("Biruni Labs") for a total consideration of USD14 million (equivalent to RM56 million) ("Acquisition"). Biruni Labs is principally engaged in the provision of laboratory services and mobile health services. Upon completion of the Acquisition, Biruni Labs and its following wholly-owned subsidiaries have been consolidated as subsidiaries of IHH:

- Biruni Tibbi Urunler Yonetim Organizasyon ve Saglik Hizmetleri A.S.
- Biruni Analiz ve Saglik Laboratuvar Hizmetleri Sanayi ve Ticaret A.S.
- Merkez Analitik Saglik Hizmetleri Ve Tibbi Tahliller Ticaret A.S.

The following summarises the recognised fair value of assets acquired and liabilities assumed at the date of acquisition:

	(Provisional) THPL RM'mil	(Provisional) Biruni Labs RM'mil	Total RM'mil
Identifiable assets acquired and liabilities assumed			
Property, plant and equipment	68	-	68
Other intangible assets	7	1	8
Deferred tax assets	1	-	1
Tax recoverables	3	-	3
Inventories	1	4	5
Trade and other receivables	4	12	16
Other fnancial assets	4	-	4
Cash and cash equivalents	-	6	6
Loans and borrowings	(15)	(4)	(19)
Trade and other payables	(12)	(12)	(24)
Tax payable	-	(2)	(2)
Fair value of net identifiable assets acquired	61	5	66
Net cash outflow arising from acquisition of subsidiaries			
Purchase consideration settled in cash and cash equivalents	170	56	226
Less: advanced payment made in prior year	(51)	-	(51)
Less: deferred purchase consideration	(3)	-	(3)
Less: cash and cash equivalents acquired	-	(6)	(6)
	116	50	166
Goodwill			
Total purchase consideration	170	56	226
Fair value of net identifiable assets acquired	(61)	(5)	(66)
Goodwill	109	51	160

As at 30 June 2026, the Group is in the midst of performing a purchase price allocation ("PPA") for the acquisition of THPL and Biruni Labs. The goodwill, fair value of assets acquired and liabilities assumed on acquisition of THPL and Biruni Labs would be adjusted accordingly upon completion of the PPA.

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

A12 SUBSEQUENT EVENTS

(a) On 7 August 2026, Suzhou Industrial Park Yuan Hui Health Consulting Co., Ltd., an indirect 70.1%-owned subsidiary of IHH, had been de-registered via a Member's Voluntary Liquidation.

(b) On 17 August 2026, PLife REIT issued 33,839 new PLife REIT units being part payment of base fee component of the management fee due to PTM, for the period from 1 April 2026 to 30 June 2026. Consequential thereto, PTM's unitholdings in PLife REIT increased to 1,516,268 units, leading to a less than 0.01% increase in IHH's effective interest in PLife REIT.

A13 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

There were no changes in contingent liabilities or contingent assets since the last audited consolidated financial statements for the year ended 31 December 2025.

A14 CAPITAL COMMITMENTS

	30 Jun 2026 RM'mil	31 Dec 2025 RM'mil
a. Capital expenditure commitments		
Property, plant and equipment and investment properties		
- Contracted but not provided for	841	892

A NOTES TO THE INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

A15 FAIR VALUE HIERARCHY

Fair value hierarchy

The table below analyses financial instruments carried at fair value. The different levels are defined as follows:

- Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Group can access at the measurement date.
- Level 2: Inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly.
- Level 3: Unobservable inputs for the asset or liability

		Fair value			Carrying
	Level 1	Level 2	Level 3	Total	amount
	RM'mil	RM'mil	RM'mil	RM'mil	RM'mil
30 June 2026					
Financial assets					
Unquoted shares at FVOCI[1]	-	-	205	205	205
Money market funds	-	332	-	332	332
Foreign exchange forward contracts	-	39	-	39	39
Cross currency swaps	-	11	-	11	11
Interest rate swaps	-	40	-	40	40
Interest rate caps	-	7	-	7	7
Financial liabilities					
Foreign exchange forward contracts	-	(18)	-	(18)	(18)
Interest rate swaps	-	(5)	-	(5)	(5)
Cross currency swaps	-	(26)	-	(26)	(26)
Fixed rate medium term notes	-	(3,014)	-	(3,014)	(3,028)
31 December 2025					
Financial assets					
Unquoted shares at FVOCI[1]	-	-	205	205	205
Money market funds	-	540	-	540	540
Foreign exchange forward contracts	-	47	-	47	47
Cross currency swaps	-	10	-	10	10
Interest rate swaps	-	33	-	33	33
Interest rate caps	-	5	-	5	5
Financial liabilities					
Foreign exchange forward contracts	-	(13)	-	(13)	(13)
Interest rate swaps	-	(7)	-	(7)	(7)
Cross currency swaps	-	(53)	-	(53)	(53)
Fixed rate medium term notes	-	(2,803)	-	(2,803)	(2,818)

[1]: Fair value through other comprehensive income

Refer to Section B13 for fair value gain/(loss) recognised in the statement of profit or loss.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

B1 REVIEW OF THE PERFORMANCE OF THE COMPANY AND ITS PRINCIPAL SUBSIDIARIES

	2nd quarter ended			Financial period ended		
	30 Jun 2026 RM'mil	30 Jun 2025 RM'mil	Variance %	30 Jun 2026 RM'mil	30 Jun 2025 RM'mil	Variance %
REVENUE[1]						
Singapore	1,367	1,514	-10%	2,705	3,034	-11%
Malaysia	1,341	1,166	15%	2,537	2,284	11%
India	1,041	1,050	-1%	2,026	2,044	-1%
Greater China	441	397	11%	832	810	3%
Turkiye and Europe	2,382	1,990	20%	4,721	3,993	18%
Hospital and Healthcare	**6,572**	**6,117**	**7%**	**12,821**	**12,165**	**5%**
Labs total revenue	423	432	-2%	814	866	-6%
Less: Labs inter-segment revenue	(170)	(176)	3%	(330)	(362)	9%
Labs	**253**	**256**	**-1%**	**484**	**504**	**-4%**
Others^	**3**	**4**	**-25%**	**5**	**4**	**25%**
Group (Excluding PLife REIT)	**6,828**	**6,377**	**7%**	**13,310**	**12,673**	**5%**
PLife REIT total revenue	118	111	6%	234	222	5%
Less: PLife REIT inter-segment revenue	(80)	(66)	-21%	(157)	(132)	-19%
PLife REIT	**38**	**45**	**-16%**	**77**	**90**	**-14%**
	6,866	**6,422**	**7%**	**13,387**	**12,763**	**5%**
Adjustment for hyperinflationary economy[4]	180	(124)	NM	212	(171)	NM
Group	**7,046**	**6,298**	**12%**	**13,599**	**12,592**	**8%**
EBITDA[2]						
Singapore	397	428	-7%	750	859	-13%
Malaysia	373	289	29%	689	562	23%
India	186	193	-4%	385	380	1%
Greater China	58	34	71%	89	79	13%
Turkiye and Europe	475	359	32%	974	721	35%
Hospital and Healthcare	**1,489**	**1,303**	**14%**	**2,887**	**2,601**	**11%**
Labs	**95**	**95**	**0%**	**177**	**180**	**-2%**
Others^	**(16)**	**(26)**	**38%**	**(76)**	**(59)**	**-29%**
Eliminations [3]	**(2)**	**-**	**-**	**(2)**	**-**	**-**
Group (Excluding PLife REIT)	**1,566**	**1,372**	**14%**	**2,986**	**2,722**	**10%**
PLife REIT	**96**	**87**	**10%**	**189**	**173**	**9%**
Eliminations[3]	**(77)**	**(67)**	**-15%**	**(156)**	**(136)**	**-15%**
	1,585	**1,392**	**14%**	**3,019**	**2,759**	**9%**
Adjustment for hyperinflationary economy[4]	22	(38)	158%	23	(62)	137%
Group	**1,607**	**1,354**	**19%**	**3,042**	**2,697**	**13%**

[1]: Relates to external revenue only.

[2]: Relates to the EBITDA performance of each strategic business units, after elimination of dividend income from within the Group.

[3]: Relates to the elimination of inter-segment income and expenses.

[4]: Arises from the application of MFRS 129.

^: "Others" comprise mainly corporate office as well as other investment holding entities.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

Q2 2026 vs Q2 2025

The Group's Q2 2026 revenue and EBITDA increased 12% and 19% respectively over Q2 2025. Excluding effects of MFRS 129, the Group's Q2 2026 revenue and EBITDA increased 7% and 14% respectively over Q2 2025.

The Group's Q2 2026 PATMI excluding exceptional items ("PATMI (Excl EI)") increased 36% to RM569 million. Excluding effects of MFRS 129, the Group's Q2 2026 PATMI (Excl EI) increased 30%.

Hospital and Healthcare

Hospital and Healthcare Q2 2026 revenue increased 7% to RM6,572 million, while EBITDA increased 14% to RM1,489 million. The growth in revenue was driven by a sustained demand for quality healthcare services, a case-mix of more acute patients and price adjustments to counter inflation. The consolidation of Bayindir Healthcare, TMI Healthcare and Biruni Labs, which were acquired after Q2 2025, also contributed to the increase in revenue.

Singapore hospital Q2 2026 inpatient admissions decreased 6% to 13,561, while revenue per inpatient admission increased 1% to RM62,618. The decrease for Singapore hospital is attributed to structural shifts towards public healthcare utilisation, and compounded by Middle East tensions which have dampened demand from certain medical travellers. Malaysia hospital Q2 2026 inpatient admissions increased 3% to 66,434, while revenue per inpatient admission increased 16% to RM13,579. India hospital Q2 2026 inpatient admissions increased 14% to 94,952, while revenue per inpatient admission increased 5% to RM8,980. Turkiye and Europe hospital Q2 2026 inpatient admissions increased 15% to 74,056, while revenue per inpatient admission increased 22% to RM15,417 with price adjustments, especially in Turkiye, to counter hyperinflation.

The increase in Hospital and Healthcare Q2 2026 EBITDA was mainly driven by higher revenue, offset by higher staff cost and other operating expense.

Labs

Labs Q2 2026 total revenue decreased 2% to RM423 million, while EBITDA was flat at RM95 million.

PLife REIT

PLife REIT Q2 2026 external revenue decreased 16% to RM38 million mainly due to the depreciation of Japanese Yen and lower rental income from the Japan portfolio due to tenant exit affecting five Japan nursing home properties. Q2 2026 EBITDA increased 10% to RM96 million with rental contributions from the Singapore hospitals.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

YTD 2026 vs YTD 2025

The Group's YTD 2026 revenue and EBITDA increased 8% and 13% respectively over YTD 2025. Excluding effects of MFRS 129, the Group's YTD 2026 revenue and EBITDA increased 5% and 9% respectively over YTD 2025.

The Group's YTD 2026 PATMI excluding exceptional items ("PATMI (Excl EI)") increased 22% to RM1,028 million. Excluding effects of MFRS 129, the Group's YTD 2026 PATMI (Excl EI) increased 17%.

Hospital and Healthcare

Hospital and Healthcare YTD 2026 revenue increased 5% to RM12,821 million, while EBITDA increased 11% to RM2,887 million. The growth in revenue was driven by a sustained demand for quality healthcare services, a case-mix of more acute patients and price adjustments to counter inflation. The consolidation of Bayindir Healthcare, TMI Healthcare and Biruni Labs, which were acquired after June 2025, also contributed to the increase in revenue.

Singapore hospital YTD 2026 inpatient admissions decreased 7% to 26,961, while revenue per inpatient admission decreased 1% to RM61,990. The decrease for Singapore hospital is attributed to structural shifts towards public healthcare utilisation, and compounded by Middle East tensions which have dampened demand from certain medical travellers. Malaysia hospital YTD 2026 inpatient admissions was flat at 126,978, while revenue per inpatient admission increased 14% to RM13,610. India hospital YTD 2026 inpatient admissions increased 14% to 184,163, while revenue per inpatient admission increased 5% to RM8,913. Turkiye and Europe hospital YTD 2026 inpatient admissions increased 14% to 149,609, while revenue per inpatient admission increased 25% to RM15,010 with price adjustments, especially in Turkiye, to counter hyperinflation.

The increase in Hospital and Healthcare YTD 2026 EBITDA was mainly driven by higher revenue, offset by higher staff cost and other operating expense.

Labs

Labs YTD 2026 total revenue decreased 6% to RM814 million, while EBITDA decreased 2% to RM177 million.

PLife REIT

PLife REIT YTD 2026 external revenue decreased 14% to RM77 million mainly due to the depreciation of Japanese Yen and lower rental income from the Japan portfolio due to tenant exit affecting five Japan nursing home properties. YTD 2026 EBITDA increased 9% to RM189 million with rental contributions from the Singapore hospitals.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

B2 MATERIAL CHANGE IN QUARTERLY RESULTS

	2nd quarter ended 30 Jun 2026 RM'mil	1st quarter ended 31 Mar 2026 RM'mil	Variance %
REVENUE[1]			
Singapore	1,367	1,338	2%
Malaysia	1,341	1,196	12%
India	1,041	985	6%
Greater China	441	391	13%
Turkiye and Europe	2,382	2,339	2%
Hospital and Healthcare	**6,572**	**6,249**	**5%**
Labs total revenue	423	391	8%
Less: Labs inter-segment revenue	(170)	(160)	-6%
Labs	**253**	**231**	**10%**
Others^	**3**	**2**	**50%**
Group (Excluding PLife REIT)	**6,828**	**6,482**	**5%**
PLife REIT total revenue	118	116	2%
Less: PLife REIT inter-segment revenue	(80)	(77)	-4%
PLife REIT	**38**	**39**	**-3%**
	6,866	**6,521**	**5%**
Adjustment for hyperinflationary economy[4]	180	32	NM
Group	**7,046**	**6,553**	**8%**
EBITDA[2]			
Singapore	397	353	12%
Malaysia	373	316	18%
India	186	199	-7%
Greater China	58	31	87%
Turkiye and Europe	475	499	-5%
Hospital and Healthcare	**1,489**	**1,398**	**7%**
Labs	**95**	**82**	**16%**
Others^	**(16)**	**(60)**	**73%**
Eliminations [3]	**(2)**	**-**	**-**
Group (Excluding PLife REIT)	**1,566**	**1,420**	**10%**
PLife REIT	**96**	**93**	**3%**
Eliminations[3]	**(77)**	**(79)**	**3%**
	1,585	**1,434**	**11%**
Adjustment for hyperinflationary economy[4]	22	1	NM
Group	**1,607**	**1,435**	**12%**

[1]: Relates to external revenue only.
[2]: Relates to the EBITDA performance of each strategic business units, after elimination of dividend income from within the Group.
[3]: Relates to the elimination of inter-segment income and expenses.
[4]: Arises from the application of MFRS 129.
^: "Others" comprise mainly corporate office as well as other investment holding entities.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

Q2 2026 vs Q1 2026

The Group's quarter-on-quarter revenue increased 8%, while EBITDA increased 12%. Excluding effects of MFRS 129, the Group's quarter-on-quarter revenue increased 5%, while EBITDA increased 11%.

The Group's quarter-on-quarter PATMI (Excl EI) increased 23%. Excluding effects of MFRS 129, the Group's quarter-on-quarter PATMI (Excl EI) increased 24%.

Hospital and Healthcare

Hospital and Healthcare quarter-on-quarter revenue increased 5%, while EBITDA increased 7%.

Singapore hospital quarter-on-quarter inpatient admissions increased 1%, while revenue per inpatient admission increased 2%. Malaysia hospital quarter-on-quarter inpatient admissions increased 10%, while revenue per inpatient admission increased 2%. India hospital quarter-on-quarter inpatient admissions increased 6%, while revenue per inpatient admission increased 2%. Turkiye and Europe hospital quarter-on-quarter inpatient admissions decreased 2%, while revenue per inpatient admission increased 6%.

Labs

Labs quarter-on-quarter total revenue increased 8%, while EBITDA increased 16%.

PLife REIT

Plife REIT quarter-on-quarter external revenue decreased 3% mainly due to the depreciation of Japanese Yen, while EBITDA increased 3% with rental contributions from the Singapore hospitals.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

B3 CURRENT YEAR FINANCIAL PROSPECTS

The demand for quality healthcare across the Group's key markets remains resilient, underpinned by favourable demographic trends, increasing healthcare awareness, and growing demand for specialised and complex care services. While the operating environment is influenced by broader macroeconomic and geopolitical uncertainties, the Group remains focused on executing its long-term strategy to deliver sustainable growth and value creation.

The Group is closely managing ongoing cost pressures arising from wage inflation, medical consumables, pharmaceuticals, utilities and other operating expenses. To further strengthen its operational resilience and support margin sustainability, the Group is advancing its multi-year transformation initiatives, including technology enablement, digitalisation, operational standardisation and productivity enhancement programmes across its markets. These initiatives are expected to progressively improve efficiency, optimise resource utilisation and support quality patient outcomes.

The healthcare reimbursement landscape remains dynamic, with insurers, corporate payors and regulators focused on affordability, utilisation management and sustainable healthcare costs. The Group will continue to work collaboratively with stakeholders across the healthcare ecosystem, while maintaining its commitment to clinical excellence, patient safety and the delivery of value-based healthcare solutions.

The Group's diversified geographical footprint, broad service offerings and strong market positions provide resilience against market-specific challenges. Geopolitical developments, including tensions in the Middle East, have some near-term impact such as the deferment of elective procedures by certain medical travellers. However, the impact is limited and largely mitigated by the Group's extensive network. This diversification enables the Group to manage risks effectively while executing differentiated growth strategies across its operating markets.

Nevertheless, the Group remains exposed to foreign exchange movements across its operating markets relative to the Malaysian Ringgit, which may affect reported earnings and margins.

Barring any unforeseen circumstances, the Group is cautiously optimistic that it is well-positioned to leverage its strong fundamentals, disciplined capital allocation approach and diversified portfolio to deliver sustainable growth and create value for its stakeholders.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

B4 PROFIT FORECAST/GUARANTEE

Not applicable as no profit forecast/guarantee was issued.

B5 TAXATION

	2nd quarter ended		Financial period ended	
	30 Jun 2026 RM'mil	30 Jun 2025 RM'mil	30 Jun 2026 RM'mil	30 Jun 2025 RM'mil
Current tax expense	194	158	295	276
Deferred tax expense	115	2	311	21
	309	160	606	297

Q2 2026 and YTD 2026 effective tax rates* were 30.2% and 30.5% respectively. Q2 2025 and YTD 2025 effective tax rates* were 22.3% and 20.1% respectively.

Acibadem Holdings recognised deferred tax debits of RM127 million and RM274 million in Q2 2026 and YTD 2026 respectively, arising from the change in regulations in Turkiye to disallow the revaluation of certain assets in the tax financials of entities in Turkiye, from 2025 till 2027. The change in regulation was effected in December 2025. Excluding this, Q2 2026 and YTD 2026 effective tax rates* would be 17.8% and 16.7% respectively.

The Group's effective tax rates differ from the Malaysia statutory tax rate mainly due to certain non-taxable income and non-tax deductible expenses (refer to page 2 for list of exceptional items).

*: Effective tax rate, after adjusting for the Group's share of profits of associates and joint ventures.

B6 STATUS OF CORPORATE PROPOSALS

There were no other corporate proposals announced but not completed as at 27 August 2026.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

B7 LOANS, BORROWINGS AND OVERDRAFTS

(a) Breakdown of the Group's loans, borrowings and overdrafts:

	30 Jun 2026 RM'mil	31 Dec 2025 RM'mil
Non-current		
Secured		
Bank loans	770	1,213
Loans from corporates	4	8
Unsecured		
Bank loans	3,409	3,680
Redeemable non-convertible debentures	575	611
Floating rate medium term notes	999	998
Fixed rate medium term notes	1,344	1,218
Loans from corporates*	6	6
	7,107	7,734
Current		
Secured		
Bank overdrafts	80	52
Bank loans	912	1,086
Loans from corporates	10	11
Unsecured		
Bank loans	2,226	1,282
Redeemable non-convertible debentures	102	108
Floating rate medium term notes	-	650
Fixed rate medium term notes	1,684	1,600
Loans from corporates*	855	861
	5,869	5,650
Total	12,976	13,384

*: Includes loans from non-controlling interests of RM860 million (2025: RM866 million).

Breakdown of the Group's loans, borrowings and overdrafts by source currency, in RM equivalent:

	30 Jun 2026 RM'mil	31 Dec 2025 RM'mil
Ringgit Malaysia	3,602	4,234
Hong Kong Dollar	2,533	2,576
Japanese Yen	2,086	2,117
Singapore Dollar	1,446	844
Indian Rupees	1,136	1,417
Renminbi	826	767
Turkish Lira	764	826
Euro	561	576
Others	22	27
	12,976	13,384

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

B8 FINANCIAL DERIVATIVE INSTRUMENTS

The Group's outstanding net derivative financial instruments as at 30 June 2026:

	Notional amount as at 30 Jun 2026 RM'mil	Fair value amount as at 30 Jun 2026 RM'mil
Derivative assets		
Foreign exchange forward contracts		
- Within 1 year	88	12
- Between 1 - 3 years	123	27
	211	39
Interest rate swaps		
- Within 1 year	350	*
- Between 1 - 3 years	383	9
- More than 3 years	708	31
	1,441	40
Interest rate caps		
- Within 1 year	284	2
- More than 3 years	160	5
	444	7
Cross currency swaps		
- Within 1 year	76	3
- Between 1 - 3 years	180	8
	256	11
	2,352	97
Derivative liabilities		
Interest rate swaps		
- Within 1 year	223	(1)
- Between 1 - 3 years	366	(4)
	589	(5)
Foreign exchange forward contracts		
- Within 1 year	331	(7)
- Between 1 - 3 years	81	(8)
- More than 3 years	112	(3)
	524	(18)
Cross currency swaps		
- Within 1 year	736	(16)
- Between 1 - 3 years	460	(10)
	1,196	(26)
	2,309	(49)

* Denotes balances of less than RM 1 million

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

Foreign exchange forward contracts

Foreign exchange forward contracts are entered by the Group to hedge against exchange rate exposures on some balances denominated in currencies other than the functional currency of the entity that recognised the foreign currency balances. The fair value of foreign exchange forward contract is determined based on prevailing market rate.

Interest rate caps

Interest rate caps are entered by the Group to protect against an increase in interest rates beyond the pre-determined cap rate.

Cross currency interest rate swaps and cross currency swaps

Cross currency interest rate swaps and cross currency swaps are entered by the Group to hedge the interest rate fluctuations on the floating rate borrowings, and to realign certain borrowings to the same currency of the Group's foreign investments to achieve a natural hedge. The fair values of cross currency interest rate swaps and cross currency swaps are determined based on bank quotes.

Interest rate swaps

Interest rate swaps are entered by the Group to hedge against interest rate fluctuations on some floating rate borrowings. The fair value of interest rate swaps is determined based on bank quotes.

There are no changes to the Group's financial risk management policies and objectives in managing these derivative financial instruments and its related accounting policies. Refer to Section B13 for the fair value gain/loss recognised in the statement of profit or loss.

B9 FAIR VALUE CHANGES OF FINANCIAL LIABILITIES

Other than as disclosed in Section A15 the Group does not remeasure its financial liabilities and derivatives at reporting date. The changes in fair value recognised through profit or loss are disclosed in Section B13.

B10 MATERIAL LITIGATIONS

The following are the material litigations of the Group:

1) In respect of Escorts Heart Institute and Research Centre Limited ("EHIRCL"), an indirect subsidiary of IHH:

   (a) The Delhi Development Authority ("DDA") had terminated the lease deeds and allotment letters relating to land parcels on which a hospital of EHIRCL exists. The matter is currently pending before the High Court of Delhi. Consequent to the termination, DDA issued show cause notice and initiated eviction proceedings against EHIRCL. The eviction proceedings initiated before the Estate Officer were challenged before the Supreme Court of India. The Supreme Court of India, vide its order dated 14 November 2019, has quashed the show cause notice for eviction proceedings. Based on external legal counsel advice, EHIRCL will be able to suitably defend the termination of lease deeds and allotment letters and accordingly considers that no adjustments are required to the financial statements.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

(b) In relation to the judgement of the High Court of Delhi relating to provision of free treatment/beds to patients of the economically weaker sections of society, the Directorate of Health Services ("DoHS"), Government of NCT of Delhi, appointed a firm to calculate "unwarranted profits" arising to EHIRCL due to alleged non-compliance. Following various hearings and appeals between 2014 and 2018, DoHS in May 2018, passed an order imposing a demand of INR5 billion (equivalent to RM238 million) which was challenged by EHIRCL before the High Court of Delhi. Through an order dated 1 June 2018, the High Court of Delhi has issued notice and directed that no coercive steps may be taken subject to EHIRCL depositing a sum of INR50 million (equivalent to RM2 million) before the DoHS. EHIRCL deposited INR50 million (equivalent to RM2 million) on 20 June 2018. Matter is sub judice before the High Court of Delhi. Based on its internal assessment and advice from its counsel, on the basis of the documents available, EHIRCL believes that it is in compliance of the conditions of free treatment and free beds to patients of economic weaker sections, has a good case of success. and expects the demand to be set aside.

2) In respect of NTK:

On 16 October 2023, NTK had filed a claim against Daiichi in the Tokyo District Court ("Court") in Japan on the basis that Daiichi has caused losses to NTK by preventing NTK from proceeding with the Fortis Open Offer and the Malar Open Offer ("Claim"). The Claim is a tort claim premised on Daiichi's unlawful interference with NTK's trade or business, conspiracy of Daiichi and other persons, malicious falsehood and defamation under the applicable substantive laws.

On 9 May 2025, NTK submitted to the Court a petition to increase the amount claimed by NTK under the Claim ("Petition to Increase Claim") and a copy of the Petition to Increase Claim was delivered to Daiichi by the Court on 20 May 2025. Pursuant to the Petition to Increase Claim, NTK is seeking the following reliefs from Daiichi, in accordance with the applicable substantive laws: (i) to pay INR109.3 billion (equivalent to RM5.2 billion) for losses arising from NTK's tortious claim (other than defamation) against Daiichi; (ii) to pay JPY5 million (equivalent to RM0.1 million) for losses arising from NTK's defamation claim against Daiichi; (iii) to pay the accrued interest on the damages claimed; (iv) by way of injunction, the prohibition from defaming NTK in the future; and (v) to publish statement on Daiichi's website and to deliver a statement to SEBI for purposes of vindicating NTK's reputation.

On 12 February 2026, NTK has submitted to the Court a petition to further amend NTK's claim against Daiichi ("2nd Petition to Amend Claims") and the copy of the 2nd Petition to Amend Claims was delivered to Daiichi by the Court on 17 February 2026. As a background, NTK has previously sought by way of injunction, to refrain Daiichi from obstructing the Fortis Open Offer and Malar Open Offer by making defamatory statements to the SEBI and to any other third parties, including the public at large ("the Injunctive Claim").

Pursuant to the completion of the Fortis Open Offer and Malar Open Offer on 10 November 2025, the 2nd Petition to Amend Claims has been filed with the Court to amend the Injunctive Claim to prevent Daiichi from obstructing the acquisition of shares and any other investment and corporate exercises in respect of Fortis and Malar by NTK, by making defamatory statements to SEBI and to any other third parties, including the public at large, in accordance with applicable substantive laws. Apart from this, there is no change to the other reliefs sought by NTK from Daiichi.

On 28 April 2026, the Court has concluded the preparatory and oral proceedings for the Claim. The announcement of judgment is scheduled for 10 September 2026.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

B11 DIVIDENDS

The Board of Directors have declared that an interim single tier cash dividend of 5.5 sen per ordinary share for the financial year ending 31 December 2026 to be paid on 30 October 2026 to shareholders whose names appear in the Record of Depositors of Bursa Malaysia Depository Sdn Bhd and The Central Depository (Pte) Limited ("CDP") at the close of business on 30 September 2026. The Company shall apply the RM:SGD noon middle rate as disclosed in the Bank Negara Malaysia's website on 30 September 2026 as the basis for computing the dividend quantum to be paid in SGD to the Singapore investors whose Company's shares are traded on SGX-ST.

For details of the dividends declared by the Company during the financial period ended 30 June 2026 and paid as at 27 August 2026, please refer to Section A7.

B12 EARNINGS PER SHARE ("EPS")

Basic earnings per share were calculated by dividing the Group's net profit attributable to shareholders by the weighted average number of ordinary shares in issue during the financial period.

	2nd quarter ended		Financial period ended	
	30 Jun 2026	30 Jun 2025	30 Jun 2026	30 Jun 2025
	RM'mil	RM'mil	RM'mil	RM'mil
Basic and diluted earnings per share is based on:				
Net profit attributable to ordinary shareholders	573	443	1,101	957
Net profit attributable to ordinary shareholders (excluding EI)	569	419	1,028	844
Basic EPS				
	million	million	million	million
Weighted average number of shares	8,836	8,824	8,836	8,820
	sen	sen	sen	sen
Basic EPS	6.48	5.02	12.46	10.85
Basic EPS (excluding EI)	6.44	4.75	11.63	9.57

Diluted earnings per share

For diluted EPS, the weighted average number of ordinary shares in issue is adjusted to assume conversion of all potentially dilutive ordinary shares.

	2nd quarter ended		Financial period ended	
	30 Jun 2026	30 Jun 2025	30 Jun 2026	30 Jun 2025
	million	million	million	million
Weighted average number of ordinary shares used in calculation of basic earnings per share	8,836	8,824	8,836	8,820
Weighted average number of unissued ordinary shares from share options under EOS	-	2	-	3
Weighted average number of dilutive ordinary shares for computation of diluted EPS	8,836	8,826	8,836	8,823
	sen	sen	sen	sen
Diluted EPS	6.48	5.02	12.46	10.85
Diluted EPS (excluding EI)	6.44	4.75	11.63	9.57

At 30 June 2026, there were no outstanding EOS options. At 30 June 2025, no outstanding EOS options were excluded from the diluted weighted average number of ordinary shares calculation.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2026

B13 NOTES TO THE STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	2nd quarter ended		Financial period ended	
	30 Jun 2026	30 Jun 2025	30 Jun 2026	30 Jun 2025
	RM'mil	RM'mil	RM'mil	RM'mil
Dividend income	1	1	2	1
Other operating income	94	80	205	168
Foreign exchange differences	4	-	12	4
Impairment loss made:				
- Property, plant and equipment	-	(3)	-	(20)
- Trade and other receivables	(12)	(15)	(38)	(39)
Write off:				
- Property, plant and equipment	(4)	-	(5)	(1)
- Trade and other receivables	(5)	(3)	(9)	(5)
- Inventories	(1)	(2)	(3)	(3)
Impairment for investment in an associate	1	-	-	-
Gain on disposal of property, plant and equipment	4	2	6	3
Gain on disposal of an investment property	2	-	2	-
Finance income				
Interest income	96	43	149	93
Exchange gain on net borrowings	-	10	-	10
Fair value gain on financial instruments	1	16	6	23
	97	69	155	126
Finance costs				
Interest on loans and borrowings	(192)	(194)	(386)	(389)
Interest on lease liabilities	(60)	(48)	(118)	(99)
Exchange (loss)/gain on net borrowings	(6)	5	(13)	-
Fair value loss on financial instruments	(3)	(5)	(3)	(18)
Other finance costs	(19)	(15)	(35)	(33)
	(280)	(257)	(555)	(539)